Toggle SGML Header (+)


Section 1: 8-K (JFM Q3 FY20 EARNINGS SLIDES)

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549
 


 
 FORM 8-K
 
 

 
CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  April 17, 2020

 
graphic 
THE PROCTER & GAMBLE COMPANY

PROCTERPROCTER & GAMBLE Coo
 (Exact Name of Registrant as Specified in Charter)   
 
 
   
  
 
 
 
 
Ohio 
 
001-00434
 
31-0411980
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
 
 
 
One Procter & Gamble Plaza, Cincinnati, Ohio 45202
 (Address of Principal Executive Offices, and Zip Code)  

  
513-983-1100
Registrant’s Telephone Number, Including Area Code  

   (Former Name or Former Address, if Changed Since Last Report)   
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
   
 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   



Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

   
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, without Par Value
PG
New York Stock Exchange
4.125% EUR notes due December 2020
PG20A
New York Stock Exchange
0.275% Notes due 2020
PG20
New York Stock Exchange
2.000% Notes due 2021 PG21 New York Stock Exchange
2.000% Notes due 2022
PG22B New York Stock Exchange
1.125% Notes due 2023
PG23A New York Stock Exchange
0.500% Notes due 2023
PG24A
New York Stock Exchange
0.625% Notes due 2024 PG24B New York Stock Exchange
1.375% Notes due 2025
PG25 New York Stock Exchange
4.875% EUR notes due May 2027
PG27A New York Stock Exchange
1.200% Notes due 2028
PG28 New York Stock Exchange
1.250% Notes due 2029
PG29B New York Stock Exchange
1.800% Notes due 2029
PG29A New York Stock Exchange
6.250% GBP notes due January 2030
PG30
New York Stock Exchange
5.250% GBP notes due January 2033
PG33
New York Stock Exchange
1.875% Notes due 2038 PG38 New York Stock Exchange

 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
Emerging growth company

       
  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended tramsition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐ 


 
 
 
ITEM 7.01    REGULATION FD DISCLOSURE
 
On April 17, 2020, The Procter & Gamble Company (the "Company") issued a press release announcing its third quarter results and hosted a conference call related to those results. The Company is furnishing on Form 8-K a series of slides referenced in the conference call, which are also posted on the Company's website.
 
This 8-K is being furnished pursuant to Item 7.01, "Regulation FD Disclosure."


ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS
 
(d) Exhibits

Exhibit Number
 
Description
99.1
 
Informational Slides Provided by The Procter & Gamble Company dated April 17, 2020.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
THE PROCTER & GAMBLE COMPANY
 
 
BY:  /s/ Sandra T. Lane                    
                Sandra T. Lane
              Assistant Secretary
              April 17, 2020





INDEX TO EXHIBIT(S)
 
 
 


(Back To Top)

Section 2: EX-99.1 CHARTER (JFM Q3 FY20 EARNINGS SLIDES)

 Earning
 Earnings Release  Q3 FY 2020April 17, 2020 
 

 Business ResultsQ3 FY 2020 
 

 IMMEDIATE PRIORITIES    Ensuring the health and safety of the men and women of P&G around the world.Maximizing the availability of products that help people and their families with their health, hygiene and cleaning needs.Helping society meet and overcome the challenges they face. 
 

 SUPERIORITYTO WIN WITH CONSUMERS  LEADING CONSTRUCTIVE DISRUPTION  FOCUSED & AGILE ORGANIZATION  ENDURING STRATEGIES  PORTFOLIO: DAILY USE, PERFORMANCE DRIVES BRAND CHOICE  PRODUCTIVITY TO FUEL INVESTMENTS                                                                                                                            Products  Packaging  Value  New StandardOf Excellence  Communication  Retail Execution     
 

 Q3 FY 2020 HIGHLIGHTS   
 

 Q3 Fiscal Year 2020  Organic Sales Growth  Organic Volume Growth  Core EPS Growth  Free Cash Flow Productivity  Q3 FY ‘20  +6%  +6%  +10%  113%  Currency Neutral Core EPS Growth  +15% 
 

 Q3 FY 2020 RESULTSORGANIC SALES GROWTH  Organic sales were driven by volume and pricing. Organic volume up +6%, pricing +1% and mix flat. 
 

 Q3 FY 2020 RESULTSCORE EPS GROWTH  Core gross margin +120 basis pointsCore operating margin +100 basis pointsTotal productivity savings +240 basis points 
 

 Q3 FY 2020 RESULTSCURRENCY-NEUTRAL CORE EPS GROWTH  Core gross margin ex-FX +130 basis pointsCore operating margin ex-FX +180 basis points 
 

 

 Business Segment Results and HighlightsQ3 FY 2020 
 

 +2% Pricing, -2% MixGlobal value share increased 0.2 versus year agoNet Earnings: Pricing help was more than offset by negative mix from volume loss on premium SK-II brand, brand communication investments and currency headwinds.  Q3 FY 2020 RESULTSBEAUTY SEGMENT 
 

 Hair Care organic sales increased low single digits versus year ago. North America, Europe, Latin America and APAC regions all grew organic sales mid- to high single digits driven by premium mix and strong retail execution. Greater China organic sales declined double digits primarily due to temporary disruption of consumer access to retail markets.Skin & Personal Care organic sales increased low single digits versus year ago with growth in Personal Care and North America Skin Care mostly offset by softness of the SK-II business in Asia. North America sales grew double digits driven by Olay premium product innovation and consumer stock-up in Personal Care. Greater China sales declined double digits with Personal Care (Safeguard) double digit sales growth more than offset by declines on premium SK-II, including travel retail, and Olay Skin related to temporary disruption of consumer access to retail markets.  Q3 FY 2020 RESULTSBEAUTY HIGHLIGHTS 
 

 +2% Pricing, -2% Mix Global value share increased 0.8 points versus year ago. Net Earnings: Pricing and productivity savings were more than offset by tax benefit in base year period, currency headwinds and negative geographic mix.  Q3 FY 2020 RESULTSGROOMING SEGMENT 
 

 Grooming organic sales declined low single digits versus year ago. Shave Care organic sales declined low single digits driven by negative mix due to volume decline in North America due to limited distribution capacity. Greater China had double digit volume decline related to temporary disruption of consumer access to retail markets. Latin America grew organic sales high single digits driven by innovation and devaluation-driven pricing. Appliances sales increased high single digits driven by premium innovation driven volume.   Q3 FY 2020 RESULTSGROOMING HIGHLIGHTS 
 

 +1% Pricing, +1% MixGlobal value share increased 0.8 points versus year agoNet Earnings: Innovation driven volume growth, pricing and productivity savings were partially offset by brand communication investments and currency headwinds.   Q3 FY 2020 RESULTSHEALTH CARE SEGMENT 
 

 Oral Care organic sales increased mid-single digits versus year ago. North America sales grew mid-single digits driven by Power toothbrushes, premium toothpaste innovation and pricing. Latin America grew strong double digits driven by innovation-driven volume and pricing. Greater China declined double digits due to temporary disruption of consumer access to retail markets.Personal Health Care organic sales increased high teens versus year ago led by innovation-driven volume, increased brand communication investments, increased consumer consumption and pantry loading and positive mix due to disproportionate growth in North America.  Q3 FY 2020 RESULTSHEALTH CARE HIGHLIGHTS 
 

 Flat Pricing, +1% MixGlobal value share increased 0.7 points versus year agoNet Earnings: Innovation-driven volume growth and productivity savings were partially offset by investments in brand communication and lower margin product mix hurt and currency headwinds.  Q3 FY 2020 RESULTSFABRIC & HOME SEGMENT 
 

 Fabric Care organic sales grew high single digits versus year ago. Broad based growth led by premium innovation-driven volume growth across laundry and fabric enhancers. North America delivered double digit and Europe delivered mid-single digit organic sales growth led by innovation, market growth and increased consumer consumption and pantry loading. China Fabric Care declined double digits due to temporary disruption of consumer access to retail markets.Home Care organic sales increased mid-teens with strong growth across all segments: Dish, Air and Surface. Sales increased from innovation-driven volume, superior retail execution and increased consumer consumption and pantry loading in North America and Europe regions.  Q3 FY 2020 RESULTSFABRIC & HOME HIGHLIGHTS 
 

 Flat Pricing, Flat MixGlobal value share declined 0.3 points versus year agoNet Earnings: Volume growth, productivity savings and commodity tailwinds were partially offset by brand communication investments, lower margin product mix hurt and currency headwinds.   Q3 FY 2020 RESULTSBABY, FEMININE and FAMILY CARE SEGMENT 
 

 Baby Care organic sales increased low single digits with growth of premium products and increased consumer demand due to consumption behaviors and pantry stocking across North America, Europe and Asia Pacific regions partially offset by mid-single digit decline in Greater China related to temporary disruption of consumer access to retail markets.Feminine Care organic sales increased high single digits versus year ago led by strong volume growth across markets driven by premium innovation and favorable product mix from Always Discreet growth.Family Care organic sales increased double digits driven by a sharp increase in consumer demand due to consumption behaviors and pantry loading, partially offset by negative product/size mix.  Q3 FY 2020 RESULTSBABY, FEMININE and FAMILY CARE HIGHLIGHTS 
 

 FY 2020 Guidance 
 

   FY ‘20  Organic Sales Growth  +4% to +5%   All-in Sales Growth (adjusted)  +3% to +4%   Maintained guidance of organic sales growth guidance +4% to +5%Adjusted all-in sales growth to +3% to +4%Includes a two point negative impact from foreign exchange, partially offset by a modest positive impact from acquisitions and divestitures.  FY 2020 GuidanceSALES 
 

   FY ‘20  Core EPS Growth   +8% to +11%  All-in EPS Growth   +235% to +245%  Maintained Core EPS growth to +8% to +11% Core effective tax rate range of 17% to 18% Maintained all-in EPS of +235% to +245% with the Gillette Shave Care carrying value adjustment in the base period (Q4). Impact in base is $3.03 on FY and $3.02 in Q4.  FY 2020 GuidanceEARNINGS PER SHARE 
 

  Adj. Free Cash Flow Productivity: 100% Capital Spending, % Sales: 4.5% to 5.0%Dividends: Over $7.5BDirect Share Repurchase: $7 to $8B  FY 2020 GuidanceCASH GENERATION AND USAGE 
 

 Significant deceleration of market growth ratesSignificant currency weaknessSignificant commodity cost increasesAdditional geo-political disruptions and economic volatility  FY 2020 GuidancePOTENTIAL HEADWINDS NOT INCLUDED IN GUIDANCE 
 

 Forward Looking Statements  Certain statements in this release or presentation, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to factors outside of our control, such as natural disasters, acts of war or terrorism, or disease outbreaks; (5) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials, and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third party information technology systems, networks and services, and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political conditions (including the United Kingdom’s exit from the European Union) and potential implications such as exchange rate fluctuations and market contraction; (13) the ability to successfully manage regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, data protection, tax, environmental, and accounting and financial reporting) and to resolve pending matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations including maintaining our intended tax treatment of divestiture transactions; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes, while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; and (17) the ability to successfully manage the demand, supply, and operational challenges associated with a disease outbreak, including epidemics, pandemics, or similar widespread public health concerns (including the novel coronavirus, COVID-19, outbreak). For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to our most recent 10-K, 10-Q and 8-K reports. 
 



The Procter & Gamble Company Regulation G Reconciliation of Non-GAAP Measures

The following provides definitions of the non-GAAP measures used in Procter & Gamble's April 17, 2020 earnings call, associated slides, and other materials and the reconciliation to the most closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e. trends excluding non-recurring or unusual items) and results and provide a supplemental measure of year-on-year results. The non-GAAP measures described below are used by Management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors as they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management. Certain of these measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in place of the related GAAP measure, but rather as supplemental information to our business results.  These non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted. The Company is not able to reconcile its forward-looking non-GAAP adjusted cash flow productivity and effective tax rate measures because the Company cannot predict the timing and amounts of discrete items such as acquisition and divestitures, which could significantly impact GAAP results.

The measures provided are as follows:
1.
Organic sales growth — page 3
2.
Core EPS and currency-neutral Core EPS — page 4
3.
Core gross margin and currency-neutral Core gross margin — page 6
4.
Core operating profit margin and currency-neutral Core operating profit margin — page 6
5.
Free cash flow productivity — page 6
6.
Adjusted free cash flow productivity — page 6

Organic sales growth*:  Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures, the impact from the July 1, 2018 adoption of new accounting standards for “Revenue from Contracts with Customers”, and foreign exchange from year-over-year comparisons. Management believes this measure provides investors with a supplemental understanding of underlying sales trends by providing sales growth on a consistent basis.

The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:
Incremental restructuring:  The Company has had and continues to have an ongoing level of restructuring activities.  Such activities have resulted in ongoing annual restructuring related charges of approximately $250 - $500 million before tax. In 2012 the Company began a $10 billion strategic productivity and cost savings initiative that included incremental restructuring activities.  In 2017, the Company communicated details of an additional multi-year productivity and cost savings plan.  This results in incremental restructuring charges to accelerate productivity efforts and cost savings.  The adjustment to Core earnings includes only the restructuring costs above what we believe are the normal recurring level of restructuring costs.
Early debt extinguishment charges: In fiscal 2018, the Company recorded after-tax charges of $243 million, due to the early extinguishment of certain long-term debt. These charges represent the difference between the reacquisition price and the par value of the debt extinguished.
Transitional Impact of U.S. Tax Act:  In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Act").  This resulted in a net charge of $602 million for the fiscal year 2018. The adjustment to Core earnings only includes this transitional impact.  It does not include the ongoing impacts of the lower U.S. statutory rate on the respective years’ earnings.
Gain on Dissolution of the PGT Healthcare Partnership: The Company finalized the dissolution of our PGT Healthcare partnership, a venture between the Company and Teva Pharmaceuticals Industries, Ltd (Teva) in the OTC consumer healthcare business, in the quarter ended September 30, 2018. The transaction was accounted for as a sale of the Teva portion of the PGT business; the Company recognized an after-tax gain on the dissolution of $353 million.
Shave Care Impairment: In the fourth quarter of fiscal 2019, the company recognized a one-time, non-cash, after-tax charge of $8.0 billion ($8.3 billion before tax) to adjust the carrying values of the Shave Care reporting unit. This was comprised of a before and after-tax impairment charge of $6.8 billion related to goodwill and an after-tax impairment charge of $1.2 billion ($1.6 billion before tax) to reduce the carrying value of the Gillette indefinite-lived intangible assets.
Anti-dilutive Impacts: The Shave Care impairment charges caused certain equity instruments that are normally dilutive (and hence normally assumed converted or exercised for the purposes of determining diluted net earnings per share) to be anti-dilutive. Accordingly, for U.S. GAAP diluted earnings per share, these instruments were not assumed to be concerted or exercised. Specifically, in the fourth quarter and total fiscal 2019, the weighted average outstanding preferred shares were not included in the diluted weighted average common shares outstanding. Additionally, in the fourth quarter of fiscal 2019, none of our outstanding share-based equity awards were included in the diluted weighted average common shares outstanding. As a result of the non-GAAP Shave Care impairment adjustment, these instruments are dilutive for non-GAAP earnings per share.
We do not view the above items to be part of our sustainable results, and their exclusion from core earnings measures provides a more comparable measure of year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation. Management views the following non-GAAP measures as useful supplemental measures of Company performance and operating efficiency over time.

Core EPS and currency-neutral Core EPS*:  Core earnings per share, or Core EPS, is a measure of the Company's diluted net earnings per share from continuing operations adjusted as indicated.  Currency-neutral Core EPS is a measure of the Company's Core EPS excluding the incremental current year impact of foreign exchange.

Core gross margin: Core gross margin is a measure of the Company's gross margin adjusted for items as indicated.

Currency-neutral Core gross margin: Currency-neutral Core gross margin is a measure of the Company's Core gross margin excluding the incremental current year impact of foreign exchange.

Core operating profit margin*: Core operating profit margin is a measure of the Company's operating margin adjusted for items as indicated.

Currency-neutral Core operating profit margin*: Currency-neutral Core operating profit margin is a measure of the Company's Core operating profit margin excluding the incremental current year impact of foreign exchange.

Free cash flow:  Free cash flow is defined as operating cash flow less capital spending. Free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion.  Management views free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investment.

Free cash flow productivity*:  Free cash flow productivity is defined as the ratio of free cash flow to net earnings.  Management views free cash flow productivity as a useful measure to help investors understand P&G’s ability to generate cash. Free cash flow productivity is used by management in making operating decisions, allocating financial resources and for budget planning purposes.  The Company's long-term target is to generate annual free cash flow productivity at or above 90 percent.

Adjusted free cash flow:  Adjusted free cash flow is defined as operating cash flow less capital spending and adjustments for items as indicated. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion.  Management views adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investment.

Adjusted free cash flow productivity*:  Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings adjusted for items as indicated.  Management views adjusted free cash flow productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in making operating decisions, allocating financial resources and for budget planning purposes.  The Company's long-term target is to generate annual free cash flow productivity at or above 90 percent.

* Measure is used to evaluate senior management and is a factor in determining their at-risk compensation.


1. Organic sales growth:
Three Months Ended
March 31, 2020
Net Sales Growth
 
Foreign Exchange Impact
 
Acquisition &
Divestiture Impact/Other*
 
Organic Sales Growth
Beauty
(1)%
 
2%
 
-%
 
1%
Grooming
(3)%
 
3%
 
(1)%
 
(1)%
Health Care
7%
 
2%
 
-%
 
9%
Fabric Care & Home Care
8%
 
1%
 
1%
 
10%
Baby, Feminine & Family Care
6%
 
1%
 
-%
 
7%
Total P&G
5%
 
2%
 
(1)%
 
6%
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.



Nine Months Ended
March 31, 2020
Net Sales Growth
 
Foreign Exchange Impact
 
Acquisition &
Divestiture Impact/Other*
 
Organic Sales Growth
Total P&G
5%
 
2%
 
(1)%
 
6%
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.



Organic Sales
Prior Quarters

 
Total Company
Net Sales Growth
 
Foreign Exchange Impact
 
Acquisition/ Divestiture Impact/Other*
 
Organic Sales Growth
JAS 2018
-%
 
3%
 
1%
 
4%
OND 2018
-%
 
4%
 
-%
 
4%
JFM 2019
1%
 
5%
 
(1%)
 
5%
AMJ 2019
4%
 
4%
 
(1)%
 
7%
JAS 2019
7%
 
2%
 
(2)%
 
7%
OND 2019
5%
 
1%
 
(1)%
 
5%

* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures for all periods, the impact from the July 1, 2018 adoption of new accounting standards for "Revenue from Contracts with Customers" and rounding impacts necessary to reconcile net sales to organic sales.



Organic Sales
Guidance
Total Company
 
Net Sales Growth
 
Combined Foreign Exchange &
Acquisition/Divestiture Impact/Other*
 
Organic Sales Growth
FY 2020 (Estimate)
 
3% to 4%
 
1%
 
+4% to +5%
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.


2. Core EPS and currency-neutral Core EPS: 
 
Three Months Ended
March 31
 
2020
 
2019
Diluted Net Earnings Per Share
$1.12
 
$1.04
  Incremental Restructuring
0.05
 
0.02
Core EPS
$1.17
 
$1.06
Percentage change vs. prior period
10%
   
Currency Impact to Earnings
0.05
   
Currency-Neutral Core EPS
$1.22
   
Percentage change vs. prior period Core EPS
15%
   

Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction.


 
Nine Months Ended
March 31
 
2020
 
2019
Diluted Net Earnings Per Share
$3.89
 
$3.48
  Incremental Restructuring
0.07
 
0.07
  Gain on Dissolution of PGT Partnership
   
(0.13)
Core EPS
$3.96
 
$3.42
Percentage change vs. prior period
16%
   
Currency Impact to Earnings
0.09
   
Currency-Neutral Core EPS
$4.05
   
Percentage change vs. prior period Core EPS
18%
   

Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction.



Core EPS
Prior Quarters

 

JAS 18
JAS 17
OND 18
OND 17
JFM 19
JFM 18
AMJ 19
AMJ 18
JAS 19
JAS 18
OND 19
OND 18
Diluted Net Earnings Per Share from Continuing Operations, attributable to P&G
$   1.22
$   1.06
$   1.22
$   0.93
$   1.04
$   0.95
$   (2.12)
$   0.72
$   1.36
$   1.22
$ 1.41
$1.22
Incremental Restructuring
0.03
0.03
0.03
0.02
0.02
0.04
0.06
0.14
0.01
0.03
0.01
0.03
Early Debt Extinguishment Charges
     
-
     
0.09
       
Transitional Impact of U.S. Tax Act
     
0.24
 
0.01
 
(0.02)
       
Gain on Dissolution of PGT Partnership
(0.14)
               
(0.14)
   
Shave Care Impairment
           
3.02
         
Anti-dilutive Impacts
           
0.14
         
Rounding
0.01
           
0.01
 
0.01
   
Core EPS
$   1.12
$   1.09
$   1.25
$   1.19
$   1.06
$   1.00
$   1.10
$   0.94
$   1.37
$   1.12
$1.42
$1.25
Percentage change vs. prior period
3%
 
5%
 
6%
 
17%
 
22%
 
14%
 
Currency Impact to Earnings
0.09
 
0.09
 
0.09
 
0.08
 
0.02
 
0.02
 
Currency-Neutral Core EPS
$   1.21
 
$   1.34
 
$   1.15
 
$   1.18
 
$1.39
 
$1.44
 
Percentage change vs. prior period Core EPS
11%
 
13%
 
15%
 
26%
 
24%
 
15%
 




Core EPS
Guidance
Total Company
Diluted EPS Growth
Impact of Incremental
Non-Core Items*
Core EPS Growth
FY 2020 (Estimate)
+235% to +245%
(227)% to (234)%
+8% to +11%

* Includes the gain on the dissolution of the PGT Healthcare partnership and Shave Care impairment in fiscal 2019 and year-over-year changes in incremental non-core restructuring charges.



3. Core gross margin:
 
Three Months Ended
March 31
 
2020
2019
Gross Margin
49.4%
48.8%
  Incremental Restructuring
1.0%
0.4%
Core Gross Margin
50.4%
49.2%
Basis point change vs. prior year Core margin
120
 
Currency Impact to Margin
0.1%
 
Currency-Neutral Core Gross Margin
50.5%
 
Basis point change vs prior year Core margin
130
 


4. Core operating profit margin: 
 
Three Months Ended
March 31
 
2020
2019
Operating Profit Margin
20.1%
19.6%
  Incremental Restructuring
0.9%
0.3%
  Rounding
(0.1)%
 
Core Operating Profit Margin
20.9%
19.9%
Basis point change vs. prior year Core margin
100
 
Currency Impact Margin
0.8%
 
Currency-Neutral Core Operating Profit Margin
21.7%
 
Basis point change vs. prior year Core Margin
180
 


5. Free cash flow productivity (dollar amounts in millions): 

Three Months Ended March 31, 2020
Operating Cash Flow
Capital Spending
Free Cash Flow
Net Earnings
Free Cash Flow Productivity
$4,064
$(731)
$3,333
$2,957
113%


6. Adjusted free cash flow productivity (dollar amounts in millions):

Nine Months Ended March 31, 2020
Operating Cash Flow
Capital Spending
U.S. Tax Act Payments
Adjusted Free Cash Flow
Net Earnings
Adjusted Free Cash Flow Productivity
$12,597
$(2,415)
$215
$10,397
$10,317
101%





(Back To Top)